Risk factor
Very poor trading liquidity
Profitability factor
Undervalued vs peers
About
Prince Pharmaceutical Co., Ltd. operates in the production and global sale of active pharmaceutical ingredients (APIs), primarily focusing on vitamin B1. Its market presence extends across Taiwan, Japan, Korea, and other international territories. The company's product portfolio also encompasses a variety of consumer health items and general medicines. These offerings include popular formulations such as vitamin C tablets and vitamin B complex tablets, alongside specialized supplements like natto and rhodiola extract capsules, probiotic sachets, and various plant extract capsules. In addition to vitamin B1, Prince Pharmaceutical supplies a comprehensive array of other APIs, notably felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. The company's distribution network specifically includes countries within Spain and the wider European continent. Established in 1962, Prince Pharmaceutical Co., Ltd. is based in Yunlin County, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, reaso